Career history of Fernando Doñate
Former positions of Fernando Doñate
| Companies | Position | Start | End |
|---|---|---|---|
| Attenuon, LLC | Corporate Officer/Principal | - | - |
Proacta, Inc.
 Proacta, Inc. BiotechnologyHealth Technology Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA. | Chief Tech/Sci/R&D Officer | 2010-02-21 | - |
| Corporate Officer/Principal | 2008-02-29 | 2010-02-21 |
Training of Fernando Doñate
| University of Missouri | Doctorate Degree |
| Universidad Complutense de Madrid | Undergraduate Degree |
Statistics
International
| United States | 4 |
| Spain | 2 |
Operational
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sectoral
| Consumer Services | 3 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Proacta, Inc.
Proacta, Inc. BiotechnologyHealth Technology Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA. | Health Technology |
| Attenuon, LLC |
- Stock Market
- Insiders
- Fernando Doñate
- Experience
